Jian Qiu

Dr. Jian Qiu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 January 2024 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MPMingang Pan
Mingang Pan
MLMuyu Luo
Muyu Luo
LLLele Liu
Lele Liu
YCYunmeng Chen
Yunmeng Chen
ZCZiyi Cheng
Ziyi Cheng
JXJie Xia
Jie Xia
Background: Hepatocellular Carcinoma (HCC) is a matter of great global public health importance; however, its current therapeutic effectiveness is deemed inadequate, and the range of therapeutic targets is limited. The aim of this study was to identify early growth response 1 (EGR1) as a transcription factor target in HCC and to explore its role and assess the potential of gene therapy utilizing EGR1 for the management of HCC. Methods: In this study, both in vitro and in vivo assays were employed to examine the impact of EGR1 on the growth of HCC. The mouse HCC model and human organoid assay were utilized to assess the potential of EGR1 as a gene therapy for HCC. Additionally, the molecular mechanism underlying the regulation of gene expression and the suppression of HCC growth by EGR1 was investigated. Results: The results of our investigation revealed a notable decrease in the expression of EGR1 in HCC. The decrease in EGR1 expression promoted the multiplication of HCC cells and the growth of xenografted tumors. On the other hand, the excessive expression of EGR1 hindered the proliferation of HCC cells and repressed the development of xenografted tumors. Furthermore, the efficacy of EGR1 gene therapy was validated using in vivo mouse HCC models and in vitro human hepatoma organoid models, thereby providing additional substantiation for the anti-cancer role of EGR1 in HCC. The mechanistic analysis demonstrated that EGR1 interacted with the promoter region of phosphofructokinase-1, liver type (PFKL), leading to the repression of PFKL gene expression and consequent inhibition of PFKL-mediated aerobic glycolysis. Moreover, the sensitivity of HCC cells and xenografted tumors to sorafenib was found to be increased by EGR1. Conclusion: Our findings suggest that EGR1 possesses therapeutic potential as a tumor suppressor gene in HCC, and that EGR1 gene therapy may offer benefits for HCC patients.

1 February 2013 in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Verified
Journal Article
Closed access
JQJian Qiu
Jian Qiu
PPPrasoon Pankaj
Prasoon Pankaj
HJHui Jiang
Hui Jiang
YZYong Zeng
Yong Zeng
HWHong Wu
Hong Wu
Laparoscopy-assisted distal gastrectomy (LADG) is one of the most accepted laparoscopic procedures in the field of gastric surgery. However, currently this procedure for the advanced gastric cancer (AGC) has still not reached the area of the popularization. The aim of this study was to compare laparoscopy with open distal gastrectomy in AGC patients using the meta-analytical techniques. The Medline Ovid, PubMed, Cochrane Library, and the Controlled Trials Registry were electronically searched. Randomized controlled trails and retrospective case-control studies, which were published between 2001 and 2011 on the management of AGC were collected on the basis of the predetermined eligibility criteria to establish a literature database. Meta-analysis was performed using RevMan 5.0 software (Cochrane Library). There were no randomized controlled trails available online; 7 case-control studies involving 1271 patients, of which 626 (49.2%) were laparoscopic and 645 (50.3%) were open procedures, were included in final pooled analysis. Meta-analysis results showed that LADG patients had a longer operative time [mean difference (MD), 37.2; 95% confidence interval (CI), 19.92 to 54.72, PConclusions: The oncologic outcomes of LADG for AGC patients were comparable with open approach. Although open distal gastrectomy may be associated with shorter operative time, patients undergoing laparoscopic approach may be benefitted from a shorter hospital stay and a faster resumption without translation into an increase in both postoperative morbidity and mortality. Nevertheless, further prospective, controlled studies, and extended follow-up are needed for a more comprehensive comparison between the 2 procedures.

30 April 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YCYajin Chen
Yajin Chen
DYDu Cheng You
Du Cheng You
SSShunli Shen
Shunli Shen
WZWu Zhang
Wu Zhang
YSYunfeng Shan
Yunfeng Shan
CHChunyi Hao
Chunyi Hao
Purpose: This phase II, multicenter, prospective, single-arm study aimed to evaluate the efficacy and safety of toripalimab plus bevacizumab for treating advanced hepatocellular carcinoma (HCC). Patients and Methods: Treatment-naïve patients with advanced HCC received toripalimab 240 mg plus bevacizumab 15 mg/kg every 3 weeks. The primary endpoints included safety and tolerability and objective response rate (ORR) assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Results: Fifty-four patients were enrolled between April 17, 2020, and December 11, 2020. As assessed by the investigator according to RECIST v1.1, the ORR was 31.5% [95% confidence interval (CI), 19.5–45.6] and the lower bound of the 95% CI was above the prespecified boundary of 10%. The independent review committee (IRC) assessed ORR according to the modified RECIST (mRECIST), which was 46.3% (95% CI, 32.6–60.4). The median progression-free survival was 8.5 (95% CI, 5.5–11.0) and 9.8 months (95% CI, 5.6 to not evaluable) as assessed by the investigator according to RECIST v1.1 and IRC according to mRECIST criteria, respectively. The median overall survival (OS) was not reached, and the 12- and 24-month OS rates were 77.3% and 63.5%, respectively. Grade 3 or higher treatment-emergent adverse events (TEAEs) occurred in 27 patients (50.0%). The most common TEAEs were proteinuria (59.3%), hypertension (38.9%), increased aspartate aminotransferase (33.3%), increased amylase (29.6%), decreased platelet count (27.8%), and increased bilirubin levels (27.8%). Conclusions: Toripalimab plus bevacizumab showed a favorable efficacy and safety profile, supporting further studies on this combination regimen as a first-line treatment for advanced HCC.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
WTWei Tang
Wei Tang
JQJian Qiu
Jian Qiu
YCYang Cai
Yang Cai
LCLuo Cheng
Luo Cheng
DYDu Cheng You
Du Cheng You
Background. Living donor liver transplantation (LDLT) provides an alternative to deceased donor liver transplantation (DDLT) for patients with end‐stage liver disease in the circumstance of scarcity of deceased grafts. However, the outcomes of LDLT remain controversial. Method. A systematic review and meta‐analysis were performed to compare the outcomes of LDLT with DDLT. Twelve outcomes were assessed. Results. Thirty‐nine studies involving 38563 patients were included. LDLT was comparable in red blood cell transfusion, perioperative mortality, length of hospital stay, retransplantation rate, hepatitis C virus recurrence rate, and hepatocellular carcinoma recurrence rate with DDLT. Cold ischemia time was shorter and duration of recipient operation was longer in LDLT. Postoperative intra‐abdominal bleeding rate occurred less frequently in LDLT recipients (odds ratio (OR) = 0.64, 95%confidence interval (CI) = 0.46 − 0.88, P = 0.006), but this did not decrease the perioperative mortality. LDLT was associated with significantly higher biliary (OR = 2.23, 95%CI = 1.59 − 3.13, P < 0.00001) and vascular (OR = 2.00, 95%CI = 1.31 − 3.07, P = 0.001) complication rates and better overall survival (OS) (1 year: OR = 1.32, 95%CI = 1.01 − 1.72, P = 0.04; 3 years: OR = 1.39, 95%CI = 1.14 − 1.69, P = 0.0010; and 5 years: OR = 1.33, 95%CI = 1.04 − 1.70, P = 0.02). According to subgroup analysis, biliary complication rate and OS improved dramatically as experience increased, while vascular complication rate could not be improved because it was mainly caused by the difference of the donor type itself. Conclusions. LDLT remains a valuable option for patients in need of liver transplantation for it provides an excellent alternative to DDLT without compromising recipient outcomes. Further refinement in biliary and vascular reconstruction techniques and the accumulation of liver transplantation centers’ experience are the key factors in expanding the application of LDLT.

1 June 2015 in HPB
Verified
Journal Article
Open access
PDF file
JQJian Qiu
Jian Qiu
SCShuting Chen
Shuting Chen
HWHong Wu
Hong Wu
Hepatic haemangioma is the most frequent benign hepatic tumour. It shows a female predominance in all age groups and is increasingly found incidentally on abdominal ultrasonography or computed tomography examinations.1. x 1. Kim, K.W., Kim, T.K., Han, J.K., Kim, A.Y., Lee, H.J., Park, S.H. et al. Hepatic hemangiomas: spectrum of US appearances on gray‐scale, power Doppler, and contrast‐enhanced US. Korean J Radiol. 2000; 1: 191–197 Crossref | PubMed | Scopus (13) | Google Scholar See all References , 2. x 2. Lim, K.J., Kim, K.W., Jeong, W.K., Kim, S.Y., Jang, Y.J., Yang, S. et al. Colour Doppler sonography of hepatic haemangiomas with arterioportal shunts. Br J Radiol. 2012; 85: 142–146 Crossref | PubMed | Scopus (6) | Google Scholar See all References , 3. x 3. Maruyama, M., Isokawa, O., Hoshiyama, K., Hoshiyama, A., Hoshiyama, M., and Hoshiyama, Y. Diagnosis and management of giant hepatic hemangioma: the usefulness of contrast‐enhanced ultrasonography. Int J Hepatol. 2013; : 802180 PubMed | Google Scholar See all References The overwhelming majority of haemangiomas are asymptomatic and do not require intervention. However, large haemangiomas can produce a variety of symptoms, including abdominal, shoulder and back pain, nausea, vomiting, jaundice, abdominal distension and dyspnoea. In addition, thrombocytopoenia, fever and compression of adjacent structures, rupture and consumptive coagulopathy (Kasabach–Merritt syndrome) have been reported.4. x 4. Aydin, C., Akbulut, S., Kutluturk, K., Kahraman, A., Kayaalp, C., and Yilmaz, S. Giant hepatic hemangioma presenting as gastric outlet obstruction. Int Surg. 2013; 98: 19–23 Crossref | PubMed | Scopus (11) | Google Scholar See all References , 5. x 5. Ebina, Y., Hazama, R., Nishimoto, M., Tanimura, K., Miyahara, Y., Morizane, M. et al. Resection of giant liver hemangioma in a pregnant woman with coagulopathy: case report and literature review. J Prenat Med. 2011; 5: 93–96 PubMed | Google Scholar See all References , 6. x 6. Billio, A., Pescosta, N., Rosanelli, C., Zanon, G.F., Gamba, P.G., Savastano, S. et al. Treatment of Kasabach‐Merritt syndrome by embolization of a giant liver hemangioma. Am J Hematol. 2001; 66: 140–141 Crossref | PubMed | Scopus (14) | Google Scholar See all References